We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » HHS to Review FDA’s Postmarketing Requirements, Supply Chain in FY16 Plan
HHS to Review FDA’s Postmarketing Requirements, Supply Chain in FY16 Plan
The HHS Office of Inspector General is planning to examine the FDA’s oversight of postmarketing studies of approved drugs and how well information exchange is occurring in the pharmaceutical supply chain as part of its six priorities for the agency in fiscal year 2016.